Shruti Gupta, MD, Brigham and Women’s Hospital, Boston, MA, talks on the remaining challenges in the field of onco-nephrology, including difficulty in predicting which patients will develop immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI). Key factors such as poor kidney function at baseline or history of immune-related adverse events may be an indication of patients requiring closer monitoring of kidney function. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.